ArticleHormones (Athens, Greece)2025
Genetically predicted endogenous sex hormone levels with risk of eczema or dermatitis.
Article in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesGrowing evidence suggests that endogenous sex hormones (ESH) are associated with the risk of eczema or dermatitis. However, the causal relationship is not yet clear. This study aims to examine the potential effects of ESH (sex hormone-binding globulin levels, estradiol levels, total testosterone levels) on the risk of eczema or dermatitis using a two-sample Mendelian randomization (MR) study.
methodsGenetic instruments from the largest available genome-wide association study (GWAS) for sex hormone-binding globulin levels, estradiol levels, and total testosterone levels were utilized to investigate the relationships between ESH and eczema or dermatitis. A set of complementary approaches was conducted to assess horizontal pleiotropy and potential caveats associated with this MR study.
resultsThe MR analysis suggested that higher sex hormone-binding globulin levels are associated with an increased risk of eczema or dermatitis (MR-Egger: odds ratio [OR] = 1.003, 95% confidence interval [CI]:1.001-1.005, P = 0.007; weighted median: OR = 1.003, 95CI%:1.000-1.005, P = 0.023). Additionally, a suggestive association was observed between total testosterone levels and an increased risk of eczema or dermatitis (inverse variance weighted: OR = 1.005, 95CI%: 1.001-1.010, P = 0.024). However, the results showed no causal effects of estradiol levels on eczema or dermatitis. The accuracy and robustness of these findings were confirmed through sensitivity analyses.
conclusionsThis MR study supports a causal effect of SHBG sex hormone-binding globulin and TT levels on the risk of eczema or dermatitis, whereas estradiol appears to have no effect. These findings suggest that endogenous sex hormones may serve as potential biomarkers for eczema or dermatitis, which could be relevant to population groups beyond those of Europe.
Indexed as
Identifiers
39602046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.